Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $2.32, $0.12 worse than the analyst estimate of $2.44. Revenue for the quarter came in at $624.4 million versus the consensus estimate of $641.95 million.

Aside from the impact of the cyberattack on our network in December, sales performance for the fourth quarter reflected continued momentum of many of our key life science and diagnostic product lines,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “Looking back at the year, we are encouraged by our overall performance, in particular, our core operating results that provide us with good momentum toward continued topline growth and reaching our long-term goals as we head into 2020.”

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.